Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLCG1201: Daily vs alternate-day TS-1 after resected NSCLC in the elderly
jRCTs061180089Phase 2Completed
- Sponsor
- ECRIN
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ECRIN. Primary endpoint: Feasibility. Started May 2012; status: completed.
02
Drugs
tegafur
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs061180089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180089.